In this episode of the podcast Rob is solo as he interviews Dr. Anath Shalev, a diabetes researcher turned founder of startup TIXiMED. Dr. Shalev discusses the discovery of TixnIP, a protein involved in oxidative stress in beta cells, and its potential for treating diabetes. The conversation covers the development of TIX 100, an oral medication targeting TixnIP, its implications for type 1 and type 2 diabetes, and the differences from existing diabetes treatments like SGLT2 inhibitors and GLP-1 agonists.

Topics discussed:

• Dr. Anas Shalev's background in diabetes research and founding of Tiximed

• Discovery of TixnIP and its role in beta cell health

• Potential of TIX 100 as a novel oral medication for diabetes treatment

• Comparison of TIX 100 with existing diabetes treatments like SGLT2 inhibitors and GLP-1 agonists

• Research process behind TixnIP inhibition and development of TIX 100

• Future of diabetes care, combination therapies, and impact on patients' lives

• Information about TIXiMED, clinical trials, and ways to support the research

  
  00:18  Revolutionizing Diabetes Treatment: From Researcher to Founder
  03:47  Revolutionizing Diabetes Treatment: Targeting Beta Cells and Glucagon Levels
  13:47  Revolutionizing Diabetes Treatment: Targeting Beta Cells in Type 1 and Type 2 Diabetes
  17:35  Revolutionizing Diabetes Treatment with Ticks 100: A Breakthrough in Addressing the Root Cause of the Disease
  27:35  The Limitations and Advantages of Verapamil in Diabetes Care
  29:47  Advancements in Diabetes Technology and Research: A Look into the Future
  33:04  Exploring Diabetes Treatment Innovations with Dr. Shalev